# Phase 3 breast cancer trials recruiting: 199 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 199 trials in phase 3 for breast cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 breast cancer trials: 199 rows for $9.95, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 199
- Recruiting or not yet: 199
- Read on: November 19, 2026

## Trials

The 25 newest of 199, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07915739 | Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer | Mahidol University | Phase 3 | Not yet recruiting | Breast Neoplasms | 1,760 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915739) |
| October 27, 2026 | NCT07898943 | Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority... | University Hospital, Clermont-Ferrand | Phase 3 | Not yet recruiting | Breast Cancer, Breast Surgery, Surgical Site Infection (SSI), Surgical Site Infection Prevention | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898943) |
| October 26, 2026 | NCT07894328 | A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Breast Cancer | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894328) |
| October 23, 2026 | NCT07892274 | Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Not yet recruiting | Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892274) |
| October 22, 2026 | NCT07890597 | A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative... | Pfizer | Phase 3 | Not yet recruiting | Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | 3,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890597) |
| October 19, 2026 | NCT07879911 | A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Triple Negative Breast Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879911) |
| September 18, 2026 | NCT07828054 | Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan | Mario Negri Institute for Pharmacological Research | Phase 3 | Not yet recruiting | Breast Cancer, Interstitial Lung Disease (ILD) | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828054) |
| September 18, 2026 | NCT07827573 | A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on... | Hoffmann-La Roche | Phase 3 | Recruiting | Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827573) |
| September 3, 2026 | NCT07802626 | Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing | SWOG Cancer Research Network | Phase 3 | Not yet recruiting | HR Positive/HER-2 Negative Breast Cancer | 1,084 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802626) |
| September 1, 2026 | NCT07797218 | Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC | Shanghai Jiao Tong University School of Medicine | Phase 3 | Recruiting | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797218) |
| August 25, 2026 | NCT07784036 | JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer | Chengdu JOYO pharma Co., Ltd. | Phase 3 | Not yet recruiting | Breast Cancer | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784036) |
| August 12, 2026 | NCT07761325 | Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Not yet recruiting | Breast Cancer, Aromatherapy, Chemotherapy, CINV | 374 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761325) |
| August 12, 2026 | NCT07760844 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760844) |
| August 11, 2026 | NCT07757958 | Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast Cancer | Samsung Medical Center | Phase 3 | Not yet recruiting | Breast Cancer, Node-negative Breast Cancer, Early-Stage Invasive Breast Carcinoma | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757958) |
| July 28, 2026 | NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729956) |
| July 23, 2026 | NCT07723469 | Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery | SURGE Therapeutics | Phase 3 | Not yet recruiting | TNBC - Triple-Negative Breast Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723469) |
| July 21, 2026 | NCT07717450 | Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer. | UNICANCER | Phase 3 | Not yet recruiting | Metastatic Invasive Breast Cancer | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717450) |
| July 10, 2026 | NCT07695948 | Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer... | University of Illinois Chicago | Phase 3 | Not yet recruiting | Breast Cancer | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695948) |
| July 6, 2026 | NCT07683754 | T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment... | Daiichi Sankyo | Phase 3 | Recruiting | Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683754) |
| July 1, 2026 | NCT07679360 | A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Triple Negative Breast Cancer | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679360) |
| June 26, 2026 | NCT07671885 | Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast... | Tokyo Women's Medical University | Phase 3 | Recruiting | Breast Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671885) |
| June 25, 2026 | NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669610) |
| June 25, 2026 | NCT07669467 | Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer | Sponsor not shown (see the record) | Phase 3 | Recruiting | Fatigue Related to Cancer Treatment, Breast Cancer | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669467) |
| June 15, 2026 | NCT07648914 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Breast Cancer | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648914) |
| June 15, 2026 | NCT07647328 | A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer | AstraZeneca | Phase 3 | Recruiting | ER-Positive HER2-Negative Breast Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647328) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 24 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 10 |
| Sun Yat-sen University | 6 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 5 |
| NRG Oncology | 5 |
| Women's Cancer Study Group GmbH | 4 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 4 |
| UNICANCER | 4 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 4 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 |
| [Shandong Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shandong-suncadia-medicine-co-ltd) | 3 |
| SWOG Cancer Research Network | 2 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 2 |
| Henan Cancer Hospital | 2 |
| [Jiangsu Alphamab Biopharmaceuticals Co., Ltd](https://specstream.ai/data/clinical-trials/company/jiangsu-alphamab-biopharmaceuticals-co-ltd) | 2 |
| Institut Curie | 2 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 2 |
| [Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-kelun-biotech-biopharmaceutical-co-ltd) | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| [Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical) | 2 |
| Gustave Roussy, Cancer Campus, Grand Paris | 2 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 2 |
| Seoul National University Hospital | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |

## By country

| Country | Trials |
| --- | --- |
| China | 98 |
| United States | 47 |
| France | 29 |
| Germany | 28 |
| Italy | 28 |
| Spain | 26 |
| South Korea | 25 |
| Belgium | 21 |
| Australia | 20 |
| Canada | 20 |
| Poland | 20 |
| Brazil | 19 |
| United Kingdom | 19 |
| Japan | 18 |
| Argentina | 15 |
| Taiwan | 15 |
| Turkey (Türkiye) | 15 |
| Greece | 14 |
| Mexico | 13 |
| Hong Kong | 12 |
| Netherlands | 11 |
| Portugal | 11 |
| Sweden | 11 |
| Czechia | 10 |
| Israel | 10 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Immunodermatology practices in the United States](https://specstream.ai/data/businesses/immunodermatology-practices/united-states)
- [Escrow companies in the United States](https://specstream.ai/data/businesses/escrow-companies/united-states)
- [Children's hospitals in the United States](https://specstream.ai/data/businesses/childrens-hospitals/united-states)
- [AV equipment rental companies in the United States](https://specstream.ai/data/businesses/av-equipment-rental-companies/united-states)
- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
- [Radiology practices in the United States](https://specstream.ai/data/businesses/radiology-practices/united-states)
